(NVCR) Novocure - Overview
Exchange: NASDAQ •
Country: Switzerland •
Currency: USD •
Type: Common Stock •
ISIN: JE00BYSS4X48
Stock: Tumor-Treating Fields, Optune Gio, Optune Lua
Total Rating 20
Risk 28
Buy Signal -1.81
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 70.8% |
| Relative Tail Risk | -18.7% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -1.14 |
| Alpha | -76.94 |
| Character TTM | |
|---|---|
| Beta | 1.280 |
| Beta Downside | 0.950 |
| Drawdowns 3y | |
|---|---|
| Max DD | 88.53% |
| CAGR/Max DD | -0.58 |
Description: NVCR Novocure January 17, 2026
Novocure Ltd (NASDAQ:NVCR) is a Swiss-based oncology firm that develops, manufactures, and commercializes Tumor Treating Fields (TTFields) medical devices-principally Optune Gio and Optune Lua-for solid-tumor cancers across the United States, Europe (Germany, France), Japan, Greater China, and other markets. The company’s pipeline extends TTFields into clinical trials for brain metastases, gastric, glioblastoma, liver, non-small-cell lung, pancreatic, and ovarian cancers.
Key recent metrics (FY 2023): revenue of $215 million, a cash-and-equivalents balance of $420 million, and a net loss of $115 million, reflecting ongoing R&D spend and market expansion. The TTFields market is projected to grow at a CAGR of ~12 % through 2030, driven by increasing reimbursement acceptance in the U.S. Medicare program and the broader shift toward non-chemical, device-based oncology therapies.
For a deeper, data-driven assessment of Novocure’s valuation dynamics, you may find ValueRay’s analyst toolkit useful for independent research.
Piotroski VR‑10 (Strict, 0-10) 2.0
| Net Income: -177.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.05 > 0.02 and ΔFCF/TA 1.61 > 1.0 |
| NWC/Revenue: 65.99% < 20% (prev 62.36%; Δ 3.63% < -1%) |
| CFO/TA -0.03 > 3% & CFO -34.5m > Net Income -177.7m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 1.55 > 1.5 & < 3 |
| Outstanding Shares: last quarter (111.9m) vs 12m ago 3.38% < -2% |
| Gross Margin: 75.37% > 18% (prev 0.76%; Δ 7461 % > 0.5%) |
| Asset Turnover: 49.73% > 50% (prev 47.28%; Δ 2.45% > 0%) |
| Interest Coverage Ratio: -10.38 > 6 (EBITDA TTM -107.5m / Interest Expense TTM 11.7m) |
Altman Z'' -2.93
| A: 0.31 (Total Current Assets 1.20b - Total Current Liabilities 776.0m) / Total Assets 1.36b |
| B: -0.93 (Retained Earnings -1.27b / Total Assets 1.36b) |
| C: -0.09 (EBIT TTM -121.0m / Avg Total Assets 1.29b) |
| D: -1.25 (Book Value of Equity -1.27b / Total Liabilities 1.02b) |
| Altman-Z'' Score: -2.93 = D |
Beneish M -2.98
| DSRI: 1.14 (Receivables 85.2m/67.1m, Revenue 642.3m/577.7m) |
| GMI: 1.01 (GM 75.37% / 76.41%) |
| AQI: 0.91 (AQ_t 0.01 / AQ_t-1 0.01) |
| SGI: 1.11 (Revenue 642.3m / 577.7m) |
| TATA: -0.11 (NI -177.7m - CFO -34.5m) / TA 1.36b) |
| Beneish M-Score: -2.98 (Cap -4..+1) = A |
What is the price of NVCR shares?
As of February 07, 2026, the stock is trading at USD 10.14 with a total of 1,850,284 shares traded.
Over the past week, the price has changed by -18.23%, over one month by -29.04%, over three months by -10.03% and over the past year by -55.78%.
Over the past week, the price has changed by -18.23%, over one month by -29.04%, over three months by -10.03% and over the past year by -55.78%.
Is NVCR a buy, sell or hold?
Novocure has received a consensus analysts rating of 4.14.
Therefore, it is recommended to buy NVCR.
- StrongBuy: 3
- Buy: 2
- Hold: 2
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the NVCR price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 24.1 | 137.4% |
| Analysts Target Price | 24.1 | 137.4% |
| ValueRay Target Price | 5.7 | -44.3% |
NVCR Fundamental Data Overview February 05, 2026
P/E Forward = 909.0909
P/S = 2.0643
P/B = 3.9992
P/EG = -0.47
Revenue TTM = 642.3m USD
EBIT TTM = -121.0m USD
EBITDA TTM = -107.5m USD
Long Term Debt = 194.6m USD (from longTermDebt, last quarter)
Short Term Debt = 560.6m USD (from shortTermDebt, last quarter)
Debt = 797.9m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 453.3m USD (from netDebt column, last quarter)
Enterprise Value = 1.09b USD (1.33b + Debt 797.9m - CCE 1.04b)
Interest Coverage Ratio = -10.38 (Ebit TTM -121.0m / Interest Expense TTM 11.7m)
EV/FCF = -16.69x (Enterprise Value 1.09b / FCF TTM -65.2m)
FCF Yield = -5.99% (FCF TTM -65.2m / Enterprise Value 1.09b)
FCF Margin = -10.15% (FCF TTM -65.2m / Revenue TTM 642.3m)
Net Margin = -27.66% (Net Income TTM -177.7m / Revenue TTM 642.3m)
Gross Margin = 75.37% ((Revenue TTM 642.3m - Cost of Revenue TTM 158.2m) / Revenue TTM)
Gross Margin QoQ = 73.25% (prev 73.88%)
Tobins Q-Ratio = 0.80 (Enterprise Value 1.09b / Total Assets 1.36b)
Interest Expense / Debt = 1.46% (Interest Expense 11.7m / Debt 797.9m)
Taxrate = 21.0% (US default 21%)
NOPAT = -95.6m (EBIT -121.0m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.55 (Total Current Assets 1.20b / Total Current Liabilities 776.0m)
Debt / Equity = 2.34 (Debt 797.9m / totalStockholderEquity, last quarter 341.3m)
Debt / EBITDA = -4.22 (negative EBITDA) (Net Debt 453.3m / EBITDA -107.5m)
Debt / FCF = -6.96 (negative FCF - burning cash) (Net Debt 453.3m / FCF TTM -65.2m)
Total Stockholder Equity = 353.2m (last 4 quarters mean from totalStockholderEquity)
RoA = -13.75% (Net Income -177.7m / Total Assets 1.36b)
RoE = -50.29% (Net Income TTM -177.7m / Total Stockholder Equity 353.2m)
RoCE = -22.09% (EBIT -121.0m / Capital Employed (Equity 353.2m + L.T.Debt 194.6m))
RoIC = -9.24% (negative operating profit) (NOPAT -95.6m / Invested Capital 1.03b)
WACC = 7.07% (E(1.33b)/V(2.12b) * Re(10.63%) + D(797.9m)/V(2.12b) * Rd(1.46%) * (1-Tc(0.21)))
Discount Rate = 10.63% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 2.28%
Fair Price DCF = unknown (Cash Flow -65.2m)
EPS Correlation: -1.59 | EPS CAGR: 1.72% | SUE: 3.33 | # QB: 1
Revenue Correlation: 76.52 | Revenue CAGR: 6.25% | SUE: 1.51 | # QB: 1
EPS next Quarter (2026-03-31): EPS=-0.40 | Chg30d=-0.026 | Revisions Net=-2 | Analysts=6
EPS next Year (2026-12-31): EPS=-1.49 | Chg30d=-0.007 | Revisions Net=-2 | Growth EPS=-6.8% | Growth Revenue=+5.6%
P/S = 2.0643
P/B = 3.9992
P/EG = -0.47
Revenue TTM = 642.3m USD
EBIT TTM = -121.0m USD
EBITDA TTM = -107.5m USD
Long Term Debt = 194.6m USD (from longTermDebt, last quarter)
Short Term Debt = 560.6m USD (from shortTermDebt, last quarter)
Debt = 797.9m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 453.3m USD (from netDebt column, last quarter)
Enterprise Value = 1.09b USD (1.33b + Debt 797.9m - CCE 1.04b)
Interest Coverage Ratio = -10.38 (Ebit TTM -121.0m / Interest Expense TTM 11.7m)
EV/FCF = -16.69x (Enterprise Value 1.09b / FCF TTM -65.2m)
FCF Yield = -5.99% (FCF TTM -65.2m / Enterprise Value 1.09b)
FCF Margin = -10.15% (FCF TTM -65.2m / Revenue TTM 642.3m)
Net Margin = -27.66% (Net Income TTM -177.7m / Revenue TTM 642.3m)
Gross Margin = 75.37% ((Revenue TTM 642.3m - Cost of Revenue TTM 158.2m) / Revenue TTM)
Gross Margin QoQ = 73.25% (prev 73.88%)
Tobins Q-Ratio = 0.80 (Enterprise Value 1.09b / Total Assets 1.36b)
Interest Expense / Debt = 1.46% (Interest Expense 11.7m / Debt 797.9m)
Taxrate = 21.0% (US default 21%)
NOPAT = -95.6m (EBIT -121.0m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.55 (Total Current Assets 1.20b / Total Current Liabilities 776.0m)
Debt / Equity = 2.34 (Debt 797.9m / totalStockholderEquity, last quarter 341.3m)
Debt / EBITDA = -4.22 (negative EBITDA) (Net Debt 453.3m / EBITDA -107.5m)
Debt / FCF = -6.96 (negative FCF - burning cash) (Net Debt 453.3m / FCF TTM -65.2m)
Total Stockholder Equity = 353.2m (last 4 quarters mean from totalStockholderEquity)
RoA = -13.75% (Net Income -177.7m / Total Assets 1.36b)
RoE = -50.29% (Net Income TTM -177.7m / Total Stockholder Equity 353.2m)
RoCE = -22.09% (EBIT -121.0m / Capital Employed (Equity 353.2m + L.T.Debt 194.6m))
RoIC = -9.24% (negative operating profit) (NOPAT -95.6m / Invested Capital 1.03b)
WACC = 7.07% (E(1.33b)/V(2.12b) * Re(10.63%) + D(797.9m)/V(2.12b) * Rd(1.46%) * (1-Tc(0.21)))
Discount Rate = 10.63% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 2.28%
Fair Price DCF = unknown (Cash Flow -65.2m)
EPS Correlation: -1.59 | EPS CAGR: 1.72% | SUE: 3.33 | # QB: 1
Revenue Correlation: 76.52 | Revenue CAGR: 6.25% | SUE: 1.51 | # QB: 1
EPS next Quarter (2026-03-31): EPS=-0.40 | Chg30d=-0.026 | Revisions Net=-2 | Analysts=6
EPS next Year (2026-12-31): EPS=-1.49 | Chg30d=-0.007 | Revisions Net=-2 | Growth EPS=-6.8% | Growth Revenue=+5.6%